AcelRx Pharmaceuticals (ACRX) : Traders are bullish on AcelRx Pharmaceuticals (ACRX) as it has outperformed the S&P 500 by a wide margin of 30.56% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 21.89%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 21.81% in the last 1 week, and is up 34.94% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 23.26% and the 50-Day Moving Average is 18.88%. AcelRx Pharmaceuticals, Inc. is up 7.4% in the last 3-month period. Year-to-Date the stock performance stands at -5.71%.
AcelRx Pharmaceuticals (NASDAQ:ACRX): stock turned positive on Friday. Though the stock opened at $3.08, the bulls momentum made the stock top out at $3.73 level for the day. The stock recorded a low of $3.035 and closed the trading day at $3.63, in the green by 17.86%. The total traded volume for the day was 1,215,931. The stock had closed at $3.08 in the previous days trading.
AcelRx Pharmaceuticals, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Companys lead product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02), a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03), is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief, and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.